Tirzepatide

Tirzepatide marked a structural shift in incretin research — a single engineered peptide acting at two receptors rather than one. The dual GIP and GLP-1 agonist approach produced trial results that forced a re-evaluation of what the category could achieve, and the compound has since become the benchmark against which subsequent multi-agonist designs are measured. The literature is large, recent, and dominated by well-powered clinical work. FAB Research supplies Tirzepatide in a 20mg pre-filled metered research pen for laboratory investigation.

Tirzepatide is a synthetic 39-amino-acid peptide based on the native GIP sequence, engineered for balanced agonism at both the GIP and GLP-1 receptors and acylated with a C20 fatty diacid for albumin binding and extended half-life. Research describes complementary signalling through the two receptor populations: GLP-1 receptor activity affecting insulin secretion, glucagon suppression and satiety, and GIP receptor activity additionally implicated in adipose tissue metabolism and nutrient handling. The relative contribution of the GIP arm remains an active area of mechanistic debate in the published literature.

Clinical characterisation is extensive and the mechanistic literature is developing quickly, particularly around the still-contested role of GIP receptor agonism in the compound's observed effects. Head-to-head trial data exists against single-agonist GLP-1 compounds. Research has investigated metabolic endpoints including glycaemic control and body composition across large cohorts. Ongoing mechanistic debate continues into whether GIP receptor agonism or antagonism drives observed effects. Studies have also examined GIP receptor expression and lipid handling in adipocytes. This compound sits within an active and heavily defended patent landscape.

• 5 mg per application (one metered dose)
• 4 doses per pen (20 mg total)
• Pre-filled sterile solution — no reconstitution step required
• Replace cap after each application; store refrigerated at 2–8 °C between uses

Storage: Store refrigerated at 2–8 °C in the original sealed box. Do not freeze. Protect from light.

• For in-vitro laboratory and preclinical research only — not for human or animal administration
• Dual GIP / GLP-1 agonist: studies isolating a single incretin receptor pathway must include appropriate comparators or receptor antagonists
• GIP receptor role in overall effect remains mechanistic debate in published literature — relevant for assay interpretation
• Note: tirzepatide is present in approved pharmaceutical products (Mounjaro, Zepbound); the FAB Research pen is a research compound, not a pharmaceutical product

• SURMOUNT-1 Phase 3 (Jastreboff et al., NEJM 2022): nausea (20%), diarrhoea (17%), constipation (10%), vomiting (6%) — dose-dependent, typically mild-to-moderate and transient
• Decreased appetite
• Injection site reactions
• Gallbladder-related events reported in longer-duration clinical data

Effects listed are observations from published research literature and are not predictions for any specific use. All FAB Research products are for in-vitro laboratory research — not for human or animal administration.